Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q4 2019 · 10-K
Revenue$12.28M$12.28M+100.8% vs Q4 2018 Net Income-$37.77M-$37.77MN/M vs Q4 2018 EPS, diluted—
Operating Incomederived-$39,423,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Operating Cash Flowderived
Free Cash Flowderived$39,333,000N/M Margins · derivedOperating margin-320.9%+108.1 pt vs Q4 2018
Net margin-307.5%+102.0 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 26, 2020 · 57 d after period end